Saturday, September 23, 2023
Saturday, September 23, 2023

ImpediMed Reports New Bone Data Showing Strong Correlation Between SOZO & DXA in Cancer Patients Presented at 39th Annual Miami Breast Cancer Conference

ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health is pleased to announce a poster showing strong correlation between ImpediMed’s SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was presented at the 39th Annual Miami Breast Cancer Conference on 3-6 March 2022 in Miami Beach, Florida, USA.

The Miami Breast Cancer Conference draws leaders in breast cancer care for in-depth discussions about current topics and technologies. The poster is available to registered attendees in-person and online. Abstracts will be published online following the conference in the journal Oncology.

The poster titled “The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device” demonstrated strong correlation between skeletal muscle mass (SMM) collected using SOZO and bone mineral content (BMC) collected using DXA in three groups: Healthy Subjects, R=0.92, Cancer Patients, During Treatment, R=0.86, and Cancer Patients, After Treatment, R=0.78.

The poster concluded, “Concurrent measures of SOZO SMM correlated strongly with DXA BMC demonstrating that SOZO SMM may be a useful surrogate in the clinic to provide a quick, easy, and reproducible indicator of change in BMC, particularly for those patients undergoing treatments that may affect BMC. Tracking SMM during or after cancer treatment with SOZO may provide an estimate of changes in BMC allowing clinicians to obtain additional diagnostic testing and/or consider treatment modifications.”

There are 16.9 million cancer survivors in the US and approximately 32 million worldwide. The majority of survivors are women with early-stage breast cancers and men with nonmetastatic prostate cancers.

These patients frequently receive hormonal manipulation therapies that can significantly impact their bone mineral content. These patients have a higher risk of bone fractures potentially leading to hospitalization and death. Multiple studies have a shown strong correlation between SMM and bone suggesting that a SOZO reading can provide a simple, quick, and reproducible estimate of BMC.

Expanding the use of SOZO to help care for cancer patients is central to ImpediMed’s growth strategy in oncology. Lymphedema provides a strong entry point for the adoption of SOZO into oncology practices and remains the Company’s key focus in the short term. Over the medium term, developing new broader oncology indications creates the opportunity to expand through demand for additional SOZO devices and adding new licenses to existing devices.

Bone is one of a number of potential indications on ImpediMed’s oncology product roadmap. Several large corporate accounts, as well as some prestigious institutions, have expressed an interest in the co-development of these potential indications with the goal of benefiting their cancer patients and improving health economics. The Company has initiated some small-scale clinical investigations and is currently assessing the opportunities. More information will be provided as they progress.

“Studies like this correlation analysis between SOZO and DXA begin to unlock the full potential of SOZO in cancer care,” commented Richard Carreon, Managing Director and CEO of ImpediMed. “Our Lymphedema Prevention Program is establishing SOZO in cancer centers worldwide. Adding new indications, such as bone, will open more opportunities in the oncology pathway and will make SOZO an even more essential part of cancer care.”

About SOZO Digital Health Platform

SOZO, the world’s most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed’s BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

FDA OK’s ensoETM for Use in Cardiac Ablations to Reduce Risk of Esophageal Injury

Published studies that have examined the use of ensoETM for this purpose include the pilot eCOOL-AF study, the IMPACT study and a large multi-center analysis of over 25,000 patients (in press at the Journal of the American College of Cardiology: Clinical Electrophysiology). These studies have found up to an 83 percent reduction in esophageal injuries, and a significant reduction in risk of atrioesophageal fistula (AEF), one of the most dreaded complications of ablation procedures. Receives FDA Clearance and Breakthrough Device Designation has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. This is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.

By using this website you agree to accept Medical Device News Magazine Privacy Policy